

9 June 2025



**CRISM Therapeutics Corporation**  
("CRISM", "CRISM Therapeutics" or the "Company")

**Best Paper Award**  
*Third party validation for ChemoSeed*

CRISM Therapeutics Corporation (AIM: CRTX) the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce it has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society ("CRS") for its paper "Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model".

The award, co-sponsored by CRS and Springer, recognises the most impactful and innovative original research article published in *Drug Delivery and Translational Research* during the past year. CRISM's winning paper, presents foundational research and preclinical validation for ChemoSeed, CRISM's proprietary localised chemotherapy delivery technology designed to maximise on-target efficacy while minimising systemic toxicity. It highlights ChemoSeed's translational potential as a safe and effective treatment for glioblastoma.

The award was selected by a panel of internationally recognised scientists and will be formally presented at the upcoming CRS Annual Meeting, taking place in Philadelphia, PA in July 2025.

**Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, commented:**

*"We are honoured to receive this recognition from CRS, a global authority in drug delivery science. This award not only reflects the quality of our research but provides strong third-party validation of the scientific underpinnings of ChemoSeed. It reinforces the promise of our platform to deliver targeted, sustained therapeutic action directly at the tumour site in glioblastoma patients. This accolade highlights the innovative potential of ChemoSeed and its ability to redefine treatment delivery for solid tumours. It is a testament to our team's commitment to advancing safer, more effective therapies."*

The full article is available in the February 2024 issue of *Drug Delivery and Translational Research*, published by Springer and at the following link <https://link.springer.com/article/10.1007/s13346-024-01524-x>

-Ends-

**Enquiries:**

**Company**  
**CRISM Therapeutics Corporation**  
Andrew Webb, CEO  
Chris McConville, CSO  
via Burson Buchanan

**Nomad and Broker**  
**S.P. Angel Corporate Finance LLP**  
Richard Morrison  
Adam Cowl  
+44 (0) 20 3470 0470

**Financial PR**  
**Burson Buchanan**  
Mark Court / Jamie Hooper  
CRISM@buchanancomms.co.uk  
+44 (0) 20 7466 5000

**About CRISM Therapeutics Corporation**

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM is expects to submit a clinical trial application for ChemoSeed glioblastoma in H2 2025.

For more information please visit: <https://www.crismltherapeutics.com/>

For more information on the Controlled Release Society, please visit: <https://www.controlledreleasesociety.org/>

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFFVRTIRIE